Mixture Disease Progression Model to Predict and Cluster the Long-Term Trajectory of Cognitive Decline in Alzheimer's Disease

被引:0
|
作者
Hanazawa, Ryoichi [1 ]
Sato, Hiroyuki [1 ]
Hirakawa, Akihiro [1 ]
Alzheimers Dis Neuroimaging Initiative
机构
[1] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Clin Biostat, 1-5-45 Yushima,Bunkyo Ku, Tokyo 1138510, Japan
基金
美国国家卫生研究院; 加拿大健康研究院;
关键词
Alzheimer's disease; Cognitive assessment; Disease progression model; Mixture model; Nonlinear mixed-effects model; PHOSPHORYLATED-TAU; CLINICAL-TRIALS; RISK; IMPAIRMENT; METAANALYSIS; DEMENTIA; SUBTYPES;
D O I
10.1007/s43441-024-00708-4
中图分类号
R-058 [];
学科分类号
摘要
BackgroundAlzheimer's disease (AD) is a neurodegenerative disease for which many clinical trials failed to detect treatment effects, possibly due to the heterogeneity of disease progression among the patients. Predicting and clustering a long-term trajectory of cognitive decline from the short-term cognition data of individual patients would help develop therapeutic interventions for AD.MethodsThis study developed mixture disease progression model to predict and cluster the long-term trajectory of cognitive decline in the population. We predicted the 30-year long-term trajectories of the three cognitive scales and categorized the individuals into rapid and slow cognitive decliners by applying the method, which was based on the two-component normal mixture nonlinear mixed-effects model, to the short-term follow-up data of the Mini-Mental State Examination, the 13-item Alzheimer's Disease Assessment Scale-Cognitive, and the Clinical Dementia Rating Scale-sum of boxes collected in patients with mild cognitive impairment and AD in the Alzheimer's Disease Neuroimaging Initiative.ResultsFor each cognitive scale, the models identified two distinct subpopulations, including a population of comprising approximately 10-20% of individuals experiencing rapid cognitive decline, wherein the posterior means of the differences in cognitive decline speed between the two groups ranged from 2 to 3 years. We also identified baseline background factors associated with rapid decliners for three cognitive scales.ConclusionIdentifying the risk factors associated with rapid decline of cognition by the proposed method aids in planning eligibility criteria and allocation strategy for accounting for the varying disease progression speeds among the patients enrolled in clinical trials for AD.
引用
收藏
页码:264 / 277
页数:14
相关论文
共 50 条
  • [32] Long-term treatment with galantamine in patients with Alzheimer's disease and Alzheimer's disease with cerebrovascular disease
    Feldman, H
    Van Baelen, B
    Brashear, HR
    Schwalen, S
    Kavanagh, S
    NEUROBIOLOGY OF AGING, 2004, 25 : S198 - S199
  • [33] DO MIDLIFE MOTIVATIONAL ABILITIES PREDICT COGNITIVE DECLINE AND ALZHEIMER'S DISEASE?
    Forstmeier, S.
    Mortby, M. E.
    Maercker, A.
    GERONTOLOGIST, 2010, 50 : 441 - 441
  • [34] Microglial activation and tau burden predict cognitive decline in Alzheimer's disease
    Malpetti, Maura
    Kievit, Rogier A.
    Passamonti, Luca
    Jones, P. Simon
    Tsvetanov, Kamen A.
    Rittman, Timothy
    Mak, Elijah
    Nicastro, Nicolas
    Bevan-Jones, W. Richard
    Su, Li
    Hong, Young T.
    Fryer, Tim D.
    Aigbirhio, Franklin, I
    O'Brien, John T.
    Rowe, James B.
    BRAIN, 2020, 143 : 1588 - 1602
  • [35] Does postural instability predict further cognitive decline in Alzheimer's disease?
    Yi, H-A.
    Hwang, J. H.
    Choi, M. K.
    Lee, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 565 - 565
  • [36] Long-term effect of galantamine on cognitive function in patients with Alzheimer's disease versus a simulated disease trajectory: an observational study in the clinical setting
    Nakagawa, Ryoko
    Ohnishi, Takashi
    Kobayashi, Hisanori
    Yamaoka, Toshio
    Yajima, Tsutomu
    Tanimura, Ai
    Kato, Toshiya
    Yoshizawa, Kazutake
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2017, 13 : 1115 - 1124
  • [37] Serum Calcium Predicts Cognitive Decline and Clinical Progression of Alzheimer's Disease
    Ma, Ling-Zhi
    Wang, Zi-Xuan
    Wang, Zuo-Teng
    Hou, Xiao-He
    Shen, Xue-Ning
    Ou, Ya-Nan
    Dong, Qiang
    Tan, Lan
    Yu, Jin-Tai
    NEUROTOXICITY RESEARCH, 2021, 39 (03) : 609 - 617
  • [38] Serum Calcium Predicts Cognitive Decline and Clinical Progression of Alzheimer’s Disease
    Ling-Zhi Ma
    Zi-Xuan Wang
    Zuo-Teng Wang
    Xiao-He Hou
    Xue-Ning Shen
    Ya-Nan Ou
    Qiang Dong
    Lan Tan
    Jin-Tai Yu
    Neurotoxicity Research, 2021, 39 : 609 - 617
  • [39] Cerebral correlates of the progression rate of the cognitive decline in probable Alzheimer's disease
    Nagahama, Y
    Nabatame, H
    Okina, T
    Yamauchi, H
    Narita, M
    Fujimoto, N
    Murakami, M
    Fukuyama, H
    Matsuda, M
    EUROPEAN NEUROLOGY, 2003, 50 (01) : 1 - 9
  • [40] Early GCase activity is a predictor of long-term cognitive decline in Parkinson's disease
    Oftedal, Linn
    Lange, Johannes
    Pedersen, Kenn Freddy
    Erga, Aleksander Hagen
    Dalen, Ingvild
    Tysnes, Ole-Bjorn
    Alves, Guido
    Maple-Grodem, Jodi
    TRANSLATIONAL NEURODEGENERATION, 2023, 12 (01)